Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exscientia Ltd.

http://www.exscientia.co.uk

Latest From Exscientia Ltd.

AI/ML Grows In Importance, Holds Promise in mRNA

Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.

Artificial Intelligence Vaccines

Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader

Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.

Artificial Intelligence Business Strategies

Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal

Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.

Artificial Intelligence Deals

Could Synthetic Data Predict Rare Adverse Events?

Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.

Artificial Intelligence Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Technologies
  • Other Names / Subsidiaries
    • Allcyte GmbH
UsernamePublicRestriction

Register